Cargando…

Correction to: COVID-19 research: promising tracks leading to uro-oncology

Detalles Bibliográficos
Autores principales:	Fazekas, Tamás, Szarvas, Tibor, Csizmarik, Anita, Hadaschik, Boris, Nyirády, Péter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2020
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7439631/ https://www.ncbi.nlm.nih.gov/pubmed/32816158 http://dx.doi.org/10.1007/s11255-020-02613-9

Ejemplares similares

COVID-19 research: promising tracks leading to uro-oncology
por: Tamás, Fazekas, et al.
Publicado: (2020)

Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis
por: Széles, Ádám, et al.
Publicado: (2022)

Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patients—a systematic review and meta-analysis
por: Fazekas, Tamás, et al.
Publicado: (2022)

Elevated Pre-Treatment Serum MMP-7 Levels Are Associated with the Presence of Metastasis and Poor Survival in Upper Tract Urothelial Carcinoma
por: Kovács, Petra Terézia, et al.
Publicado: (2022)

High Pretreatment Serum PD-L1 Levels Are Associated with Muscle Invasion and Shorter Survival in Upper Tract Urothelial Carcinoma
por: Széles, Ádám, et al.
Publicado: (2022)

Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients
por: Olah, Csilla, et al.
Publicado: (2020)

MMP-7 Serum and Tissue Levels Are Associated with Poor Survival in Platinum-Treated Bladder Cancer Patients
por: Szarvas, Tibor, et al.
Publicado: (2020)

High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy
por: Krafft, Ulrich, et al.
Publicado: (2021)

Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration‐resistant prostate cancer
por: Keresztes, Dávid, et al.
Publicado: (2021)

High-soluble CGA levels are associated with poor survival in bladder cancer
por: Szarvas, T, et al.
Publicado: (2019)

Robotics in uro-oncologic surgery
por: De Lorenzis, Elisa, et al.
Publicado: (2013)

Proteome profiling of enzalutamide‐resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration‐resistant prostate cancer
por: Csizmarik, Anita, et al.
Publicado: (2022)

Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study
por: Váradi, Melinda, et al.
Publicado: (2023)

Correction to: A new technological approach in diagnostic pathology: mass spectrometry imaging-based metabolomics for biomarker detection in urachal cancer
por: Neumann, Judith Martha, et al.
Publicado: (2021)

Correction: The UroLift implant: mechanism behind rapid and durable relief from prostatic obstruction
por: Roehrborn, Claus G., et al.
Publicado: (2022)

Positron emission tomography in uro-oncology
por: Hain, S F
Publicado: (2005)

Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data
por: Reis, Henning, et al.
Publicado: (2018)

Comprehensive Analysis of the Prognostic Value of Circulating MMP-7 Levels in Urothelial Carcinoma: A Combined Cohort Analysis, Systematic Review, and Meta-Analysis
por: Kubik, András, et al.
Publicado: (2023)

Why are upper tract urothelial carcinoma two different diseases?
por: Szarvas, Tibor, et al.
Publicado: (2016)

Telehealth in Uro-oncology Beyond the Pandemic: Toll or Lifesaver?
por: Rodler, Severin, et al.
Publicado: (2020)

Value of multiphoton microscopy in uro-oncology: a narrative review
por: Treacy, Patrick-Julien, et al.
Publicado: (2023)

Serum and tissue syndecan-1 levels in renal cell carcinoma
por: Niedworok, Christian, et al.
Publicado: (2020)

Application of Mass Spectrometry Imaging in Uro-Oncology: Discovering Potential Biomarkers
por: Czétány, Péter, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Uro-Oncology: Urgent Call for Biomarkers
por: Pichler, Renate
Publicado: (2020)

The Experiences of Specialist Nurses Working Within the Uro-oncology Multidisciplinary Team in the United Kingdom
por: Punshon, Geoffrey, et al.
Publicado: (2017)

Nefro-Uro /
Publicado: (2018)

Concerns in Redirecting Uro-oncologic Patients During COVID-19 Pandemic
por: Campodonico, Fabio, et al.
Publicado: (2020)

The Uro-oncology Patient and Vaccination Against SARS-CoV-2
por: Rodriguez Socarrás, Moises, et al.
Publicado: (2021)

Editorial: Technology advancements, social media and innovations in uro-oncology and endourology
por: Hameed, B M Zeeshan, et al.
Publicado: (2022)

Item analysis of G8 screening in uro-oncologic geriatric patients
por: Bouzan, J., et al.
Publicado: (2023)

The Shift Towards Digital Appointments: the Response to COVID-19 Affecting Uro-Oncology
por: Scott, E., et al.
Publicado: (2021)

Impact of COVID-19 on Uro-Oncological Patients: A Comprehensive Review of the Literature
por: Gavi, Filippo, et al.
Publicado: (2023)

Proteasomal Processing Immune Escape Mechanisms in Platinum-Treated Advanced Bladder Cancer
por: Wessolly, Michael, et al.
Publicado: (2022)

Essentials of Uro-Radiology
por: Kabala, J. E.
Publicado: (1991)

Haema-Uro-Chrome
Publicado: (1914)

Predictive value of molecular subtypes and APOBEC3G for adjuvant chemotherapy in urothelial bladder cancer
por: Olah, Csilla, et al.
Publicado: (2022)

Prevalence of APC and PTEN Alterations in Urachal Cancer
por: Nagy, Nikolett, et al.
Publicado: (2020)

Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas
por: Varadi, Melinda, et al.
Publicado: (2023)

Uro-oncologic patient management during the COVID-19 pandemic: survey findings from an Italian oncologic hub
por: Luzzago, Stefano, et al.
Publicado: (2021)

High-Risk Prostate Cancer: A Very Challenging Disease in the Field of Uro-Oncology
por: Napodano, Giorgio, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3ntuojvc8d89u88874013pmmc1